Allena Pharmaceuticals announced the treatment of the first patients in Study 206, an open-label Phase 2 basket study evaluating ALLN-177 in adults and adolescents with primary hyperoxaluria, or enteric hyperoxaluria with advanced chronic kidney disease and elevated plasma oxalate. ALLN-177 is a first-in-class, non-absorbed, orally-administered enzyme that is designed to degrade oxalate within the gastrointestinal, or GI, tract to treat severe hyperoxaluria. Severe hyperoxaluria can result from genetic causes that lead to the overproduction of oxalate by the liver or certain GI conditions that lead to the over absorption of oxalate from diet. Patients with severe hyperoxaluria are at an increased risk of developing systemic oxalosis, a potentially fatal condition that results in oxalate crystal formation throughout the body including in the blood, kidney, bones, joints, skin, eyes and heart. In patients with enteric hyperoxaluria and systemic oxalosis, high plasma oxalate levels can also lead to kidney damage and accelerated decline in renal function.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.